Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Operating Leases (2022 - 2024)

Historic Operating Leases for BioXcel Therapeutics (BTAI) over the last 3 years, with Q4 2024 value amounting to $65000.0.

  • BioXcel Therapeutics' Operating Leases fell 8522.73% to $65000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $65000.0, marking a year-over-year decrease of 8522.73%. This contributed to the annual value of $65000.0 for FY2024, which is 8522.73% down from last year.
  • According to the latest figures from Q4 2024, BioXcel Therapeutics' Operating Leases is $65000.0, which was down 8522.73% from $161000.0 recorded in Q3 2024.
  • In the past 5 years, BioXcel Therapeutics' Operating Leases ranged from a high of $1.0 million in Q1 2022 and a low of $65000.0 during Q4 2024
  • For the 3-year period, BioXcel Therapeutics' Operating Leases averaged around $562666.7, with its median value being $573000.0 (2023).
  • Per our database at Business Quant, BioXcel Therapeutics' Operating Leases crashed by 3161.48% in 2023 and then tumbled by 8522.73% in 2024.
  • Quarter analysis of 3 years shows BioXcel Therapeutics' Operating Leases stood at $786000.0 in 2022, then plummeted by 44.02% to $440000.0 in 2023, then plummeted by 85.23% to $65000.0 in 2024.
  • Its last three reported values are $65000.0 in Q4 2024, $161000.0 for Q3 2024, and $256000.0 during Q2 2024.